CN101489575B - Fkbp-l及其用途 - Google Patents

Fkbp-l及其用途 Download PDF

Info

Publication number
CN101489575B
CN101489575B CN2007800276683A CN200780027668A CN101489575B CN 101489575 B CN101489575 B CN 101489575B CN 2007800276683 A CN2007800276683 A CN 2007800276683A CN 200780027668 A CN200780027668 A CN 200780027668A CN 101489575 B CN101489575 B CN 101489575B
Authority
CN
China
Prior art keywords
fkbp
polypeptide
cell
peptide
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800276683A
Other languages
English (en)
Chinese (zh)
Other versions
CN101489575A (zh
Inventor
特拉西·罗布森
安德烈亚·瓦伦丁
马丁·奥鲁尔克
大卫·赫斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almac Discovery Ltd
Original Assignee
Almac Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almac Discovery Ltd filed Critical Almac Discovery Ltd
Publication of CN101489575A publication Critical patent/CN101489575A/zh
Application granted granted Critical
Publication of CN101489575B publication Critical patent/CN101489575B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y502/00—Cis-trans-isomerases (5.2)
    • C12Y502/01—Cis-trans-Isomerases (5.2.1)
    • C12Y502/01008—Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Dispersion Chemistry (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
CN2007800276683A 2006-06-09 2007-06-08 Fkbp-l及其用途 Expired - Fee Related CN101489575B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0611405.2A GB0611405D0 (en) 2006-06-09 2006-06-09 FKBP-L: A novel inhibitor of angiogenesis
GB0611405.2 2006-06-09
PCT/GB2007/002107 WO2007141533A2 (en) 2006-06-09 2007-06-08 Fkbp-l and uses thereof

Publications (2)

Publication Number Publication Date
CN101489575A CN101489575A (zh) 2009-07-22
CN101489575B true CN101489575B (zh) 2013-08-28

Family

ID=36745574

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800276683A Expired - Fee Related CN101489575B (zh) 2006-06-09 2007-06-08 Fkbp-l及其用途

Country Status (18)

Country Link
US (3) US9381228B2 (https=)
EP (1) EP2040728B1 (https=)
JP (1) JP5474535B2 (https=)
CN (1) CN101489575B (https=)
AU (1) AU2007255196B2 (https=)
CA (1) CA2657947C (https=)
CY (1) CY1116970T1 (https=)
DK (1) DK2040728T3 (https=)
ES (1) ES2548332T3 (https=)
GB (1) GB0611405D0 (https=)
HU (1) HUE028099T2 (https=)
IL (1) IL195580A (https=)
NZ (2) NZ573425A (https=)
PL (1) PL2040728T3 (https=)
PT (1) PT2040728E (https=)
SI (1) SI2040728T1 (https=)
WO (1) WO2007141533A2 (https=)
ZA (1) ZA200810323B (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
ES2586387T3 (es) 2003-11-05 2016-10-14 Dana-Farber Cancer Institute, Inc. Péptidos alfa helicoidales adecuados para activar o inhibir la muerte celular
US7507842B2 (en) 2005-08-12 2009-03-24 Radiorx, Inc. Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
DK2118123T3 (en) 2007-01-31 2016-01-25 Dana Farber Cancer Inst Inc Stabilized p53 peptides and uses thereof
US8592377B2 (en) 2007-03-28 2013-11-26 President And Fellows Of Harvard College Stitched polypeptides
GB0724393D0 (en) * 2007-12-14 2008-01-23 Univ Ulster Use of FKBPL gene to identify a cause of infertility
EP2356139A4 (en) 2008-07-23 2013-01-09 Harvard College LIGURE COMBINED POLYPEPTIDES
CN102203126A (zh) 2008-09-22 2011-09-28 爱勒让治疗公司 用于制备纯化的多肽组合物的方法
US9175047B2 (en) 2009-01-14 2015-11-03 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
GB0908589D0 (en) 2009-05-19 2009-06-24 Univ Belfast Assay method
AU2010273220B2 (en) 2009-07-13 2015-10-15 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
CN102712675A (zh) 2009-09-22 2012-10-03 爱勒让治疗公司 拟肽大环化合物
ES2711526T3 (es) 2010-08-13 2019-05-06 Aileron Therapeutics Inc Macrociclos peptidomiméticos
WO2012040459A2 (en) 2010-09-22 2012-03-29 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
US9487562B2 (en) 2011-06-17 2016-11-08 President And Fellows Of Harvard College Stabilized polypeptides as regulators of RAB GTPase function
US20140308260A1 (en) * 2011-10-07 2014-10-16 Radiorx, Inc. Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
BR112014020103A2 (pt) 2012-02-15 2018-10-09 Aileron Therapeutics, Inc. macrociclos peptidomiméticos
EP2819688A4 (en) 2012-02-15 2015-10-28 Aileron Therapeutics Inc TRIAZOL AND THIOETHER-COUPLED PEPTIDOMIMETIC MACROCYCLES
WO2014052647A2 (en) 2012-09-26 2014-04-03 President And Fellows Of Harvard College Proline-locked stapled peptides and uses thereof
WO2014071241A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
EP3391898A3 (en) 2013-03-13 2019-02-13 President and Fellows of Harvard College Stapled and stitched polypeptides and uses thereof
JP2016523241A (ja) 2013-06-14 2016-08-08 プレジデント アンド フェローズ オブ ハーバード カレッジ 安定化されたポリペプチドインスリン受容体調節剤
CA2949535C (en) 2014-05-21 2023-09-12 President And Fellows Of Harvard College Ras inhibitory peptides and uses thereof
EP3197478A4 (en) 2014-09-24 2018-05-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
AU2015320545C1 (en) 2014-09-24 2020-05-14 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
WO2016154058A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2017044633A1 (en) 2015-09-10 2017-03-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of mcl-1
US10342778B1 (en) 2015-10-20 2019-07-09 Epicentrx, Inc. Treatment of brain metastases using organonitro compound combination therapy
US9987270B1 (en) 2015-10-29 2018-06-05 Epicentrix, Inc. Treatment of gliomas using organonitro compound combination therapy
CN109069420A (zh) 2016-01-11 2018-12-21 埃皮辛特瑞柯斯公司 2-溴-1-(3，3-二硝基氮杂环丁烷-1-基)乙酮静脉施用的组合物和方法
US20190381127A1 (en) 2016-02-02 2019-12-19 Splash Pharmaceuticals, Inc. Combination therapy with a6, chemotherapeutic agents, radiation therapy, or a combination thereof for the treatment of cancer
JP2019523234A (ja) * 2016-06-22 2019-08-22 アルマック・ディスカバリー・リミテッドＡｌｍａｃ Ｄｉｓｃｏｖｅｒｙ Ｌｉｍｉｔｅｄ 眼疾患の処置
CN110352190A (zh) 2016-10-14 2019-10-18 埃皮辛特瑞柯斯公司 用于医疗用途的磺氧基烷基有机硝基和相关化合物和药物组合物
EP3528831B1 (en) * 2016-10-19 2022-09-21 Royal College of Surgeons in Ireland Use of fkbp-l polypeptides and nucleic acids for the treatment of obesity
CN108362870A (zh) * 2017-01-27 2018-08-03 武汉三鹰生物技术有限公司 一种用于人fkbpl蛋白的酶联免疫检测及制备方法
US11744859B2 (en) 2017-07-07 2023-09-05 Epicentrx, Inc. Compositions and methods for parenteral administration of therapeutic agents
US11510901B2 (en) 2018-01-08 2022-11-29 Epicentrx, Inc. Methods and compositions utilizing RRx-001 combination therapy for radioprotection
CN111603567B (zh) * 2019-02-22 2024-12-27 赣江新区博瑞创新医药有限公司 Cd44靶向多臂偶联物
CN113702632A (zh) * 2021-09-02 2021-11-26 深圳市光与生物科技有限公司 一种快速检测子痫前期的免疫层析检测卡及其制备方法与应用
CN114702564A (zh) * 2021-12-15 2022-07-05 江苏省人民医院（南京医科大学第一附属医院） 一种外泌体肽及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001002569A2 (en) * 1999-07-06 2001-01-11 Incyte Genomics, Inc. Human immune response molecules
CN1281465A (zh) * 1998-10-09 2001-01-24 上海第二医科大学 人fk506结合蛋白(fkbp)
WO2002044418A2 (en) * 2000-11-28 2002-06-06 Wyeth Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
US20060088836A1 (en) * 2002-04-24 2006-04-27 Jay Wohlgemuth Methods and compositions for diagnosing and monitoring transplant rejection

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3194732A (en) * 1960-10-03 1965-07-13 Neuhauser Irene Assisting healing of skin-denuded areas on the body with dried non-fibrous egg-shellmembrane products and compositions therefor
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
AU7757581A (en) 1980-11-19 1982-05-27 United Energy Technologies Inc. Enhanced surface tubing
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) * 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
US4630115A (en) 1983-05-09 1986-12-16 The General Electric Company, P.L.C. Cathode ray tube display device
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
JP3065628B2 (ja) * 1988-12-19 2000-07-17 三井化学株式会社 ヒト免疫グロブリン遺伝子関連ｄｎａ断片及び該ｄｎａ断片を用いる診断方法
US5766883A (en) * 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5073627A (en) * 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
AU648140B2 (en) * 1991-02-01 1994-04-14 Virtual Drug Development, Inc. Reverse antimicrobial peptides and antimicrobial compositions
IL99120A0 (en) * 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
PT672141E (pt) 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
CA2166278A1 (en) * 1993-06-29 1995-01-12 Denis J. Gospodarowicz A truncated keratinocyte growth factor (kgf) having increased biological activity
PT871730E (pt) * 1995-10-11 2004-11-30 Chiron Corp Combinacao de pdgf, kgf, igf e igfbp para cicatrizacao de ferimentos
CA2288351A1 (en) 1997-05-01 1998-11-05 Amgen Inc. Chimeric opg polypeptides
US6583168B1 (en) 1997-11-25 2003-06-24 Applera Corporation Sulfonated diarylrhodamine dyes
US6180095B1 (en) * 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
CA2331382A1 (en) * 1998-06-18 1999-12-23 Curagen Corporation Interaction of p27(kip1) with fkbp-12
EP1088857A4 (en) 1999-04-13 2005-01-19 Hayashibara Biochem Lab CYANINE COLOR
EP1210046A4 (en) * 1999-06-22 2007-05-02 Res Dev Foundation IMPROVED DRESSING THAT CAN ACCELERATE THE HEALING OF INJURIES
US6413507B1 (en) * 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
US20030125246A9 (en) * 2000-01-31 2003-07-03 Rosen Craig A. Nucleic acids, proteins, and antibodies
AU2002255478A1 (en) * 2001-01-10 2002-09-12 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
MXPA03011455A (es) 2001-06-22 2004-04-05 Hoffmann La Roche Complejo soluble que comprende glucoproteina de superficie retroviral.
US6856185B2 (en) * 2001-10-23 2005-02-15 Arris International, Inc. Simple RMS to DC converter
US20040053388A1 (en) * 2002-01-03 2004-03-18 Eckert Jorg H. Detection of protein conformation using a split ubiquitin reporter system
US20040047835A1 (en) * 2002-09-06 2004-03-11 Cell Therapeutics, Inc. Combinatorial drug therapy using polymer drug conjugates
AU2006259583A1 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1281465A (zh) * 1998-10-09 2001-01-24 上海第二医科大学 人fk506结合蛋白(fkbp)
WO2001002569A2 (en) * 1999-07-06 2001-01-11 Incyte Genomics, Inc. Human immune response molecules
WO2002044418A2 (en) * 2000-11-28 2002-06-06 Wyeth Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
US20060088836A1 (en) * 2002-04-24 2006-04-27 Jay Wohlgemuth Methods and compositions for diagnosing and monitoring transplant rejection

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Carl F. McAllister等.analysisi in Neisseria meningitidis and other Neisseria species of genes homologous to the FKBP immunophilin family.《molecular microbiology》.1993,第10卷(第1期), *
王耀辉.内皮细胞生长因子诱导大鼠内皮细胞增殖过程中FKBP12的表达.《第三军医大学学报》.2003,第25卷(第24期), *

Also Published As

Publication number Publication date
CY1116970T1 (el) 2017-04-05
JP5474535B2 (ja) 2014-04-16
NZ573425A (en) 2012-07-27
WO2007141533A2 (en) 2007-12-13
PL2040728T3 (pl) 2016-02-29
US20160340401A1 (en) 2016-11-24
US9381228B2 (en) 2016-07-05
EP2040728A2 (en) 2009-04-01
IL195580A (en) 2013-07-31
JP2009539367A (ja) 2009-11-19
US20090192085A1 (en) 2009-07-30
AU2007255196B2 (en) 2013-10-03
SI2040728T1 (sl) 2015-12-31
CN101489575A (zh) 2009-07-22
NZ600690A (en) 2014-03-28
US20160340402A1 (en) 2016-11-24
CA2657947C (en) 2017-11-21
ZA200810323B (en) 2013-05-29
ES2548332T3 (es) 2015-10-15
GB0611405D0 (en) 2006-07-19
IL195580A0 (en) 2011-08-01
WO2007141533A3 (en) 2008-07-31
DK2040728T3 (en) 2015-10-26
CA2657947A1 (en) 2007-12-13
HUE028099T2 (en) 2016-11-28
PT2040728E (pt) 2015-10-29
AU2007255196A1 (en) 2007-12-13
EP2040728B1 (en) 2015-09-02
US10577406B2 (en) 2020-03-03

Similar Documents

Publication Publication Date Title
CN101489575B (zh) Fkbp-l及其用途
CN109369808B (zh) 用于治疗ror1癌症并抑制转移的抗体和疫苗
ES2287020T3 (es) Procedimiento y composiciones para inhibir el crecimiento de celulas neoplasicas.
ES2776029T3 (es) Terapias basadas en el control de la estabilidad y función de las células T reguladoras por medio de un eje neuropilina-1:semaforina
BR112020026386A2 (pt) Composições e métodos para modulação de fenótipos inflamatórios com monócitos e macrófagos e usos de imunoterapia dos mesmos
CN107098970B (zh) 结合细胞内prl-1多肽或prl-3多肽的抗体
JP2021507925A (ja) Ｇｐｃｒヘテロマー阻害剤及びその用途
US7285382B2 (en) Compositions and methods for treatment of cancer
JP6309080B2 (ja) がん治療のためのｅｇｆｒ−ｓｇｌｔ１相互作用の標的化
CN101679485B (zh) 骨桥蛋白的功能表位、针对该单位的单克隆抗体及它们的应用
KR20190130604A (ko) 암 치료법에서 괴사를 표적화하기 위한 인간화 항-핵 항체
JPWO2002033094A1 (ja) Ｖｐｌｆの活性を阻害する抗体
KR20010086072A (ko) 신생 세포 성장 억제를 위한 방법 및 조성물
CN107446024A (zh) 一种可拮抗ddx3蛋白rna结合活性的多肽dip‑13及其应用
ES2268901T3 (es) Procedimientos y composiciones para la inhibicion del crecimiento celular neoplastico.
KR102125005B1 (ko) 53bp1의 신규한 용도
US20200024347A1 (en) Or10h1 antigen binding proteins and uses thereof
JP5852731B2 (ja) 高増殖性疾患治療のための医薬組成物
KR20190062149A (ko) 전이성 암 치료용 조성물
US20220267390A1 (en) Mps modified peptides and use thereof
JPWO2005061704A1 (ja) 癌の予防・治療剤
JP2003000271A (ja) 新規ポリぺプチド、新規ｄｎａ、新規抗体および新規遺伝子改変動物
HK40005045B (zh) 用於治疗ror1癌症并抑制转移的抗体和疫苗

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130828

Termination date: 20200608